Conflict of Interest Waiver Details For Cmte. Members Should Be Public – BMS
This article was originally published in The Tan Sheet
Executive Summary
FDA advisory committee members granted conflict of interest waivers should be required to disclose the companies to which they have financial ties, Bristol-Myers Squibb maintains in comments to FDA
You may also be interested in...
‘High Dollar’ Conflicts Should Nullify FDA Advisory Panelists – Public Citizen
FDA advisory committee members with large financial conflicts of interest should be recused from meetings in which these conflicts may come into play, Public Citizen recommends after conducting a study on voting patterns
FDA advisory committee conflict of interest
"Special government employees" granted conflict of interest waiver for product-specific advisory committee meetings must provide declaration prior to meeting disclosing nature, magnitude of the conflict, agency says in draft guidance released in January. Document provides guidelines on type, amount of information that must be disclosed to the public...
OTC "Actual Use Studies" Subject To Financial Disclosure Requirements
"Actual use studies" conducted in support of Rx-to-OTC switch or direct-to-OTC new drug applications and used to show effectiveness in the OTC setting are subject to FDA's financial disclosure requirements, according to a draft guidance clarifying the agency's February 1998 final rule.